[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,518,0,25,[9,47,75,99,126,164,195,222,249,269,298,325,349,373,389,456,477,507,577,601,622,639,669,688,713],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053731","lung-bases-4-life-mobile-low-dose-computed-tomography-ldct-screening-ages-40-54-100053731",false,"NCT04577599","Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54","Lung B.A.S.E.S 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Assessing Incidence and Stage of Lung Cancer Diagnosis in Subjects Ages 40-54 With a 30 Pack Year History or More Within North and South Carolina","Inclusion Criteria:\n\n* Subject must meet all the following applicable inclusion criteria to participate in this study:\n\n  1. Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n  2. Age 40-54 years at the time of consent.\n  3. A positive smoking history of greater\u002Fequal to 30 pack years and they are either currently smoking or have quit within the last 15 years.\n  4. Ability to read and understand the English and\u002For Spanish language.\n  5. Ability to understand and comply with study procedures for the entire length of the study.\n\nExclusion Criteria:\n\n* Subjects meeting any of the criteria below may not participate in the study:\n\n  1. Known diagnosis of lung cancer in the past 5 years.\n  2. Any known contraindication to having a low-dose CT Scan.\n  3. Known pregnancy.",true,"ALL","40 Years","54 Years",{"count":22,"type":23},1160,"ESTIMATED","INTERVENTIONAL",[26],"NA","Low-dose CT Screening has been shown in two large trials in the United States (NLST) and Europe (NELSON) to increase overall survival in subjects 55 years of age and older with a strong smoking history. Unfortunately, in both North Carolina (NC) and South Carolina (SC), subjects are found to have the above referenced smoking history prior to reaching the minimum age in these studies. This study is aimed at decreasing the minimum age of screening in a high-risk population.",[29,30],"Lung Neoplasms","Lung Cancer",[32,30,33],"Screening","Smoking","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2021-01-07",{"date":42,"type":23},"2028-10",{"name":44,"class":45},"Wake Forest University Health Sciences","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":24,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100053279","a-study-of-mental-health-care-in-people-with-cancer-100053279","NCT06037954","A Study of Mental Health Care in People With Cancer","Mental Health Care Initiation Intervention for Older Adults With Cancer","Inclusion Criteria:\n\nPatients\n\n* Per medical record and\u002For self-report, diagnosed with breast, colorectal, lung, or prostate cancer at age 65 years or older\n* Per medical record and\u002For self-report, undergoing active cancer treatment (e.g., radiation, chemotherapy, immunotherapy, surgery) or within six months of completing treatment\n* Score of ≥5 on the Patient Health Questionnaire-9 (PHQ-9)\n* Per self-report, fluent in English\\*\\* \\*\\* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:\n\n  1. How well do you speak English? (must respond \"very well\" or \"well\" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)\n  2. What is your preferred language for healthcare? (must respond English)\n\nProviders\n\n* Per self-report, works in oncology, nursing, social work, psychology, or psychiatry\n* Per self-report, currently works in oncology at least 50% of the time\n* Per self-report, provided cancer care for at least three years at time of consent\n* Per self-report, fluent in English\n\nExclusion Criteria:\n\nPatients\n\n* Severely cognitively impaired as demonstrated by Blessed Orientation Memory Concentration scores of ≥ 11\n* Per research staff judgment and\u002For self-report, too ill or weak to complete study procedures\n* Per medical record and\u002For self-report, receiving hospice care at the time of enrollment\n* Per medical record and\u002For self-report, currently enrolled in mental health treatment\n\nProviders\n\n* N\u002FA","65 Years",{"count":56,"type":23},130,[26],"The purpose of this study is to look at mental health services for adults with depressed mood who were diagnosed with cancer at the age of 65 or older. This study will compare the usual approach for connecting older adults with depressed mood to mental health services with the Open Door for Cancer (OD-C) approach. We will find out if the OD-C approach is practical and useful for cancer patients who participate in the intervention and for providers who see or treat cancer patients.",[60,61,30,62],"Breast Cancer","Colorectal Cancer","Prostate Cancer",[64,65,66],"65 years and older","Mental health care","23-218","2026-07-09",{"date":37,"type":38},{"date":70,"type":38},"2023-09-07",{"date":72,"type":23},"2026-09",{"name":74,"class":45},"Memorial Sloan Kettering Cancer Center",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":24,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100053551","mobile-application-to-improve-health-related-outcomes-in-patients-with-advanced-lung-cancer-100053551","NCT06427954","Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer","Randomized Trial of Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer","THRIVE","Inclusion Criteria:\n\n* Adults (greater than or equal to 18 years)\n* Diagnosed with advanced non-small cell lung cancer (NSCLC) that is not being treated with curative intent or extensive stage small cell lung cancer (SCLC) within the past 12 weeks.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 0-2 (i.e., fully active to at least ambulatory and up and about more than 50% of waking hours).\n* Sufficient English proficiency to utilize THRIVE in English (Note: patients can complete outcome measures in Spanish if preferred).\n\nExclusion Criteria:\n\n* Significant uncontrolled psychiatric disorder (e.g., psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (e.g., dementia, cognitive impairment), which the treating oncology clinician reports would prohibit the ability to participate in study procedures.","18 Years",{"count":85,"type":23},250,[26],"Multi-site randomized trial of the THRIVE digital health application versus usual care to evaluate the effect of THRIVE on quality of life (QOL), physical and psychological symptoms, coping, and self-efficacy in 250 patients with newly diagnosed advanced lung cancer.",[30],[90],"Quality of life",{"date":37,"type":38},{"date":93,"type":38},"2024-08-06",{"date":95,"type":23},"2027-12",{"name":97,"class":45},"Massachusetts General Hospital",3,{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100053816","lucinae-registry-thoracic-cancers-during-pregnancy-100053816","NCT07699861","LUCINAE Registry: Thoracic Cancers During Pregnancy","LUCINAE: LUng and Thoracic Cancers In pregNAncy rEgistry","LUCINAE","Inclusion Criteria:\n\n* 1\\. All patients with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities) and pregnancy (positive pregnancy test) including:\n\n  1. Patients receiving a diagnosis of thoracic cancer during pregnancy\n  2. Patients who became pregnant while having active thoracic cancer\n  3. Patients previously treated for a thoracic cancer and becoming pregnant in the 5 years following end of treatment OR Men with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities), who were undergoing active oncological treatment at the time their partner conceived their child.\n* 2\\. Available information about pregnancy outcomes\n* 3\\. Age ≥ 18 years\n\nExclusion Criteria:\n\n* 1\\. Patient missing data about thoracic cancer stage and diagnosis\n* 2\\. For retrospective patients, documented refusal to the use of clinical data for research purposes",{"count":108,"type":23},100,"OBSERVATIONAL","The LUCINAE Registry is an international, multicenter observational study collecting data on patients with thoracic cancers (including lung cancer) who are expecting a child. This includes women diagnosed during pregnancy, women who become pregnant during or after cancer, and men receiving cancer treatment at the time their partner conceives.\n\nBecause thoracic cancers during pregnancy are rare, there is limited information to guide clinical decisions. This registry aims to describe patient characteristics, diagnostic approaches, treatments, and maternal and fetal outcomes. Data are collected retrospectively and prospectively from participating centers.\n\nThe results of this registry are expected to improve understanding of thoracic cancers in this setting and support the development of future clinical recommendations.",[30,112,113],"Thoracic Cancer","Cancer During Pregnancy",[115,116],"thoracic cancers during pregnancy","Lung cancer during pregnancy","2026-07-07",{"date":37,"type":38},{"date":120,"type":23},"2026-06",{"date":122,"type":23},"2035-12",{"name":124,"class":45},"Oncology Institute of Southern Switzerland",4,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":24,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100597545","distance-based-exercise-to-preserve-function-and-prevent-disability-100597545","NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-",{"count":134,"type":23},104,[26],"This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[138,139,140,60,141,142,143,144,145,146,147,148,30,149,150,151,62,152,153],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Cervical Cancer","Colon Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastric Cancer","Kidney Cancer","Liver Cancer","Head and Neck Cancer","Ovarian Cancer","Pancreatic Cancer","Rectal Cancer","Sarcoma","2026-07-01",{"date":156,"type":38},"2026-07-02",{"date":158,"type":38},"2026-02-11",{"date":160,"type":23},"2027-08-31",{"name":162,"class":45},"Alliance for Clinical Trials in Oncology",18,{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":24,"phases":173,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":193,"locationsCount":46},"100643366","phase-2-olomorasib--pembrolizumab-kras-g12c-mutant-pd-l1-tps-1-49-locally-advanced-or-metastatic-nsclc-100643366","NCT07639242","Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC","Olomorasib Plus Pembrolizumab as First-Line Treatment for KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","In order to participate in this study a subject must meet all of the eligibility criteria outlined below. Eligibility must be maintained up until the point at which the subject receives treatment for the subject to be considered eligible for treatment.\n\nInclusion Criteria:\n\nIn order to participate in this study a subject must meet ALL of the eligibility criteria outlined below.\n\nWritten informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. Subject is willing and able to comply with study procedures based on the judgement of the investigator.\n\n* Age ≥ 18 years at the time of consent.\n* Eastern Cooperative Oncology Group performance status (ECOG) of 0-2\n* Subjects must have previously untreated, Stage IIIB-IIIC or Stage IV Non-Small Cell Lung Cancer (NSCLC) not amenable to curative intent treatment.\n* Measurable disease according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1 within 28 days prior to treatment\n* Known KRAS G12C mutation identified on tumor tissue or circulating tumor DNA (ctDNA) as determined by molecular testing performed in a CLIA, CAP or other similarly certified laboratory per local guidelines.\n* Subjects must have a known PD-L1 tumor proportion score (TPS) of 1-49% as determined by an IHC assay in a CLIA, CAP, or other similarly certified laboratory as per local guidelines\n\nExclusion Criteria:\n\n• Subject has a serious pre-existing medical condition(s) that, in the judgment of the Investigator, would preclude participation in this study, including interstitial lung disease (ILD) or severe dyspnea at rest and uncontrolled disease-related pericardial effusion or pleural effusion.",{"count":172,"type":23},60,[174],"PHASE2","This clinical trial evaluates the combination of olomorasib and pembrolizumab as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has a Kirsten Rat Sarcoma Virus (KRAS) G12C mutation and a programmed death-ligand (PD-L1) score between 1% and 49%. The main goal of the study is to determine how long patients live without their cancer worsening after starting treatment, also known as progression-free survival (PFS). Additional goals include evaluating how many patients experience tumor shrinkage or disappearance, how long responses to treatment last, overall survival, and the safety and side effects of the treatment combination. Furthermore, how well the treatment works in patients whose cancer has spread to the brain, outcomes in patients with a lower Eastern Cooperative Oncology Group performance status (ECOG), and whether certain tumor or blood-based biomarkers are associated with treatment response or side effects, if enough patient data is available for analysis.",[30,177,178,179],"Lung Cancer (NSCLC)","Locally Advanced NSCLC","Metastatic NSCLC - Non-Small Cell Lung Cancer",[181,182,183,184,185,186],"olomorasib","pembrolizumab","KRAS G12C+mutant","Kirsten Rat Sarcoma Virus G12C+ mutant","programmed death-ligand","PD-L1","NOT_YET_RECRUITING","2026-06-30",{"date":156,"type":38},{"date":120,"type":23},{"date":192,"type":23},"2030-06-21",{"name":194,"class":45},"UNC Lineberger Comprehensive Cancer Center",{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":24,"phases":204,"briefSummary":206,"conditions":207,"keywords":208,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":221},"100563601","phase-1-a-study-to-evaluate-the-safety-tolerability-drug-levels-and-preliminary-efficacy-of-bms-986507-combinations-in-adult-participants-with-advanced-solid-tumors-100563601","NCT06618287","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","A Phase 1\u002F2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors","Inclusion Criteria\n\n* Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Participants must have a life expectancy of at least 3 months at the time of the first dose.\n* Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed\n* Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC.\n* Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC.\n* Group D: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC per ASCO\u002FCAP criteria, based on the most recently analyzed biopsy or another pathology specimen.\n* Group E: Participants must have pathologically confirmed locally advanced or metastatic NSCLC, not amenable to treatment in curative intent.\n\nExclusion Criteria\n\n* Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.\n* Participants with known mutations in EGFR will be excluded (Group A,B and E).\n* Participants must not have a history of serious recurrent infections.\n* Participants must not have a history of severe heart disease.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":203,"type":23},416,[205,174],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.",[30,60],[209,210,211,212],"Non-Small Cell Lung Cancer (NSCLC)","Epidermal Growth Factor Receptor mutated (EGFRmt)","Epidermal Growth Factor Receptor wild-type (EGFRwt)","Triple-negative breast cancer (TNBC)",{"date":154,"type":38},{"date":215,"type":38},"2025-02-04",{"date":217,"type":23},"2031-02-26",{"name":219,"class":220},"Bristol-Myers Squibb","INDUSTRY",64,{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":229,"targetDuration":231,"studyType":109,"phases":4,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":248},"100587083","european-real-world-registry-for-use-of-the-ion-endoluminal-system-100587083","NCT06923774","European Real-World Registry for Use of the Ion Endoluminal System","A European Multi-Center, Prospective, Single-Arm, Observational Study to Evaluate Real-World Outcomes for the Ion Endoluminal System","Inclusion Criteria:\n\n* Patient is aged 18 years or older at time of consent.\n* Patient is planned to undergo a lung lesion biopsy(s) and\u002For localization procedure(s) utilizing the Ion endoluminal system.\n* Patient is willing and able to give written informed consent for clinical study participation.\n\nExclusion Criteria:\n\n* Patient is participating in an interventional research study or research study with investigational agents with an unknown safety profile that would interfere with participation in this study or study results.\n* Female patient that is pregnant or breast feeding as determined by standard site practices.\n* Patient is legally incapacitated or in a legal\u002Fcourt ordered institution or is part of a known vulnerable population, including but not limited to dependency on the sponsor, hospital or study doctor.\n* Patient is not willing to comply with post-procedure study participation requirements.\n* Investigator, in their professional opinion, has decided that it is in the patient's best interest to not participate in the clinical study.",{"count":230,"type":23},1200,"24 Months","The objective of this study is to collect collect real-world data for the Ion endoluminal system.",[234,30],"Pulmonary Nodule",[236,237,238,239],"Biopsy","Bronchoscopy","pulmonary biopsy","pulmonary nodule localization","2026-06-29",{"date":188,"type":38},{"date":243,"type":38},"2025-09-09",{"date":245,"type":23},"2029-10",{"name":247,"class":220},"Intuitive Surgical",6,{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":46},"100100354","identification-of-secreted-markers-for-tumor-hypoxia-in-patients-with-head-and-neck-or-lung-cancers-100100354","NCT00568490","Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers","Inclusion Criteria:\n\n* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.\n* Able to sign a Stanford IRB approved consent form\n\nExclusion criteria:\n\n* Refuse or unable to sign an IRB approved consent form.\n* Refuse to be contacted in the future for follow up.",{"count":256,"type":23},200,"The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.",[149,30,259,260,261],"Lip Cancer","Lip Neoplasms","Head and Neck Cancers",{"date":154,"type":38},{"date":264,"type":38},"1998-09-01",{"date":266,"type":23},"2027-06-30",{"name":268,"class":45},"Stanford University",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":17,"sex":18,"minAge":276,"maxAge":4,"enrollmentInfo":277,"targetDuration":279,"studyType":109,"phases":4,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100607264","exopert-emerald-clinical-study-100607264","NCT07186296","EXoPERT EMERALD Clinical Study","EXoPERT EMERALD: Early Multi-cancer Study of EV's Ramen-AL Linked Diagnosis Clinical Study Protocol","Inclusion Criteria:\n\n* Subject aged 45 years or older with a biopsy-proven or clinically suspected primary lung, breast, colorectal, pancreatic, or ovarian cancer, based on objective findings such as radiological, serological, endoscopic, or cytological findings, whose blood was collected prior to any systemic or definitive therapy for the cancer.\n* Subjects who are willing and able to provide written informed consent.\n* Subjects who are willing and able to comply with the study requirements.\n\nExclusion Criteria:\n\n* Any history of cancer diagnosed and treated within 5 years prior to the date of consent.\n* Subjects with a history of previous cancer treatment via surgical resection, hormonal cancer treatment, chemotherapy, radiotherapy within the past 6 months for recent cancer diagnosis.\n* Subjects who have any history of an allogeneic bone marrow, stem cell transplant, or solid organ transplant.\n* Subjects who are pregnant or breastfeeding women.\n* Subjects who have consented and have undergone treatment in any other cancer related clinical trials withinthe past 6 months.\n* Subjects who are currently in active treatment for drug abuse.\n* Subjects who have received any treatment related to lung, breast, colorectal, pancreatic, or ovarian nodules, such as hormones prior to entering the study.\n* Unsuitable sample for testing due to contamination, hemolysis, etc.","45 Years",{"count":278,"type":23},1400,"1 Day","The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhanced Raman spectroscopy (SERS) profiles of extracellular vesicles (EVs) extracted from human plasma for the early detection of multiple cancers, including lung, ovarian, breast, pancreatic, and colorectal cancers.",[60,142,151,150,30],[283,284,285,286,287,288],"Early-stage","In vitro Diagnostic Test","Artificial intelligence","extracellular vesicles","multi cancer diagnosis","cancer","2026-06-28",{"date":154,"type":38},{"date":292,"type":38},"2025-05-09",{"date":294,"type":23},"2026-08-31",{"name":296,"class":220},"EXoPERT",9,{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":24,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":98},"100615767","care-tool-study-aim-3-100615767","NCT07296887","CARE Tool Study Aim 3","Implement and Evaluate the CARE Tool in a Randomized Trial","Inclusion Criteria for Implementation champions:\n\n\\- Members of the cancer care team (e.g., physicians, nurses, research coordinators, financial navigators, social workers) that work with patients receiving treatment for gynecologic, lung, prostate, or colorectal cancer; or members of the billing team and employee of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n\nExclusion Criteria for Implementation champions:\n\n* Implementation champions are ineligible if they are non-employees of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n* Do not treat patients for gynecologic, prostate, lung, or colorectal cancer\n\nInclusion Criteria for Patients:\n\n* Age 18 and over\n* Primary or recurrent diagnosis of gynecologic, prostate, lung, or colorectal cancer in the last 12 months\n* Receiving cancer treatment from Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n* Self-reported ability to read and speak English\n\nExclusion Criteria for Patients:\n\n* Under the age of 18\n* Not diagnosed with gynecologic, prostate, lung, or colorectal cancer within the previous 12 months from recruitment\n* Not receiving care at Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n* Cannot give consent due to cognitive or emotional barriers",{"count":306,"type":23},430,[26],"This study is a multi-site randomized trial to study the implementation of the CARE Tool and evaluate the CARE Tool. The CARE Tool is a web-based tool that gives people information about cancer care costs, health insurance, and resources to help with costs. Overall, the study aims to help patients with cancer overcome barriers they face navigating insurance and accessing financial resources.",[310,62,30,61],"Gynecologic Cancer",[312,313,314,315,316],"Insurance","Insurance coverage","Cancer","Cost of medical care","Financial toxicity","2026-06-27",{"date":154,"type":38},{"date":320,"type":38},"2026-04-08",{"date":322,"type":23},"2028-07-31",{"name":324,"class":45},"Washington University School of Medicine",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":331,"enrollmentInfo":332,"targetDuration":334,"studyType":109,"phases":4,"briefSummary":335,"conditions":336,"keywords":337,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":344,"leadSponsor":346,"locationsCount":348},"100645241","label-free-femtosecond-laser-imaging-combined-with-the-fast-lung-artificial-intelligence-model-for-rapid-intraoperative-diagnosis-of-lung-surgical-specimens-a-multicentre-prospective-parallel-workflow-non-inferiority-study-100645241","NCT07681245","Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.","Inclusion Criteria:\n\n1. Preoperative imaging suggests a pulmonary nodule, pulmonary space-occupying lesion, or suspected pulmonary tumor lesion.\n2. The participant is scheduled to undergo pulmonary wedge resection, segmentectomy, lobectomy, or other pulmonary surgery.\n3. Fresh lung tissue specimens can be obtained intraoperatively for femtosecond laser imaging.\n4. Intraoperative frozen section diagnosis is planned to assess the nature of the tumor lesion.\n5. Corresponding postoperative paraffin-embedded pathological diagnosis can be obtained.\n6. The participant or the participant's legally authorized representative has signed the written informed consent form.\n\nExclusion Criteria:\n\n1. The intraoperative specimen is insufficient and cannot simultaneously meet the requirements for routine clinical pathological diagnosis and research-related testing.\n2. The specimen shows severe carbonization, necrosis, compression, contamination, or improper preservation, and the investigator determines that effective imaging cannot be completed.\n3. The femtosecond laser imaging specimen cannot be matched with the corresponding lesion assessed by final paraffin pathology.\n4. Final paraffin-embedded pathological diagnosis cannot be obtained.\n5. The participant withdraws informed consent.\n6. Other conditions that, in the opinion of the investigator, make the participant unsuitable for this study.","90 Years",{"count":333,"type":23},294,"30 Days","This study aims to evaluate whether femtosecond laser imaging combined with FastLung AI model can provide intraoperative diagnostic performance that is non-inferior to standard frozen section diagnosis for pulmonary nodules or suspected pulmonary tumor lesions. Patients scheduled for lung surgery and requiring intraoperative pathological assessment will be prospectively enrolled. After tumor excision, the fresh tumor specimen will be bisected through the central plane. One half will be used for standard frozen section diagnosis, and the mirrored counterpart will be used for femtosecond laser imaging. Both diagnostic results will be compared with the final paraffin-embedded pathological diagnosis as the reference standard. The results of femtosecond laser imaging will not guide intraoperative clinical decision-making.",[30],[338,339,340],"lung cancer","artificial intelligence","Intraoperative diagnosis","2026-06-26",{"date":156,"type":38},{"date":188,"type":23},{"date":345,"type":23},"2026-09-30",{"name":347,"class":45},"Shanghai Chest Hospital",5,{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":18,"minAge":357,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":361,"conditions":362,"keywords":363,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":371,"locationsCount":46},"100638470","observational-study-that-will-analyse-the-spread-and-stratification-of-lung-cancer-risk-using-artificial-intelligence-100638470","NCT07617636","Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial Intelligence","Artificial Intelligence for the Analysis of STAS and Lung Cancer Risk Stratification","ANASTASIA","Inclusion Criteria:\n\n* Individuals of both sexes, smokers or former smokers for a maximum of 15 years;\n\n  * Smoking history of 20 pack-years or more;\n  * Between 50 and 80 years old;\n  * Provision of Free and Informed Consent in writing, signed and dated.\n\nExclusion Criteria:\n\n* Individuals who are unable to undergo a CT scan;\n\n  * Individuals who cannot tolerate lying on their back for more than 10 minutes continuously;\n  * Individuals who present with symptoms highly suggestive of lung cancer (hemoptysis, chest pain, altered cough pattern, unintentional weight loss greater than 10 kg);\n  * Diagnosis of severe heart disease while using multiple medications;\n  * Diagnosis of severe lung disease, using multiple medications and\u002For requiring home oxygen therapy;\n  * History of radiation therapy to the chest area;\n  * Individuals undergoing cancer evaluation or treatment;\n  * Individuals exhibiting signs of respiratory distress (nasal flaring, suprasternal retraction, use of accessory muscles, cyanosis);\n  * Pregnancy.","50 Years","80 Years",{"count":360,"type":23},1500,"Observational cohort study involving individuals of both sexes with a history of smoking, residing in municipalities in the state of Bahia and attended by the mobile unit, with the aim of evaluating the integration of artificial intelligence (AI) in the detection of pulmonary nodules and the prediction of ASCT in high-risk individuals undergoing CT screening.",[30],[364,365,366],"Lung","Tumor","Artificial Intelligence",{"date":240,"type":38},{"date":369,"type":23},"2026-07-31",{"date":160,"type":23},{"name":372,"class":220},"AstraZeneca",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":358,"enrollmentInfo":380,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":387,"locationsCount":46},"100513445","exploration-of-predictive-markers-of-neoadjuvant-immunotherapy-in-non-small-cell-lung-cancer-100513445","NCT05965557","Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer","A Biomarker Study for Predicting the Response of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer Based on Circulating Tumor DNA and Homologous Recombination Deficiency Analysis","Inclusion Criteria:\n\n* Stage II-IIIB NSCLC\n* EGFR\u002FALK negative\n* The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up\n\nExclusion Criteria:\n\n* A history of other malignancies within the past 5 years\n* Patients with autoimmune disease are not suitable for PD1 monoclonal antibody therapy",{"count":108,"type":23},"Neoadjuvant immunotherapy has become the standard perioperative treatment in lung cancer, but its effective predictive biomarkers are lacking. A small cohort reported that homologous recombination deficiency (HRD) can be used as a reliable biomarker to predict the efficacy of neoadjuvant immunotherapy, but the findings need to be validated in larger cohorts. Moreover, circulating tumor DNA (ctDNA) has the potential to predict the therapeutic efficacy of neoadjuvant immunotherapy.\n\nThis study intends to prospectively collect patients with driver-negative stage II-IIIB NSCLC who are scheduled to receive neoadjuvant immunotherapy and surgical resection and verify the value of HRD in predicting the efficacy of neoadjuvant immunotherapy. Meanwhile, the blood samples before and after neoadjuvant immunotherapy were collected for high-depth ctDNA detection to explore the correlation between the dynamic changes of ctDNA and the efficacy and prognosis of neoadjuvant immunotherapy.",[30],{"date":188,"type":38},{"date":385,"type":38},"2023-06-19",{"date":95,"type":23},{"name":388,"class":220},"Geneplus-Beijing Co. Ltd.",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":17,"sex":18,"minAge":396,"maxAge":397,"enrollmentInfo":398,"targetDuration":358,"studyType":109,"phases":4,"briefSummary":400,"conditions":401,"keywords":437,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":455},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals","19 Years","110 Years",{"count":399,"type":23},999999,"The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[151,402,30,144,403,142,152,404,139,405,406,407,146,148,408,409,410,411,412,147,413,62,414,415,416,417,418,259,419,420,421,422,423,424,425,426,427,428,60,429,430,153,431,432,150,143,433,434,435,436],"Thyroid Cancer","Thymus Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Penile Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Leukemia","Melanoma","Unknown Primary Tumor","Multiple Myeloma","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[151,402,438,439,440,441,442,443,444,445,60,446,435,436],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":240,"type":38},{"date":450,"type":38},"2013-11-01",{"date":452,"type":23},"2099-12",{"name":454,"class":45},"University of Nebraska",42,{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":17,"sex":18,"minAge":276,"maxAge":463,"enrollmentInfo":464,"targetDuration":4,"studyType":24,"phases":465,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":473,"leadSponsor":475,"locationsCount":4},"100644984","precision-navigation-to-improve-community-cancer-screening-participation-a-dual-cohort-cluster-randomized-trial-100644984","NCT07676383","Precision Navigation to Improve Community Cancer Screening Participation: A Dual-Cohort Cluster Randomized Trial","Effectiveness and Mechanisms of a Precision Navigation Intervention to Improve Community Cancer Screening Participation: A Dual-Cohort Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 45 to 74 years.\n2. Permanent resident of a participating community, defined as having lived in the community for at least 6 months during the past 12 months.\n3. Participating in the urban cancer screening program.\n4. Identified by the program risk assessment questionnaire as being at high risk for at least one of the following cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer.\n5. Has not yet completed the corresponding free clinical screening test for the high-risk cancer type or types.\n6. Able to complete electronic questionnaires and read intervention materials independently or with assistance. Paper materials and staff explanation will be provided for participants who do not use smartphones.\n7. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Previously diagnosed with any of the target cancers, including lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer.\n2. Severe cognitive impairment, severe mental illness, or other conditions that prevent the participant from receiving the intervention or completing study questionnaires.\n3. Planning to be away from the community for a long period during the next 6 months, defined as cumulative absence of more than 3 months.\n4. Currently participating in another interventional study that may affect cancer screening behavior.","74 Years",{"count":360,"type":23},[26],"This study will evaluate whether a precision navigation intervention can help community residents at high risk for cancer complete recommended cancer screening. The study will be conducted in communities participating in an urban cancer screening program in China.\n\nEligible participants will be adults aged 45 to 74 years who are permanent residents of participating communities and have been identified as being at high risk for at least one of five cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. Participants must not have completed the corresponding free clinical screening before enrollment.\n\nThis is a dual-cohort, cluster randomized controlled trial. Communities, rather than individual participants, will be assigned to one of three groups: a precision navigation group, a usual health education group, or a waiting control group. Participants will be classified into two cohorts according to the number of cancers for which they are assessed as high risk. Cohort A will include participants at high risk for three or more cancers, and Cohort B will include participants at high risk for one or two cancers.\n\nParticipants in the precision navigation group will receive a personalized navigation report matched to their risk profile. The report will explain the screening tests most relevant to them, help them understand screening choices, and provide practical steps to support screening completion. Participants in the usual health education group will receive general cancer screening education materials. Participants in the waiting control group will not receive active screening promotion during the main intervention period, but will receive general education materials after the primary assessment.\n\nThe main outcome is whether participants complete the recommended cancer screening during follow-up. The study will also assess changes in screening-related decision conflict, anxiety, self-efficacy, and behavioral intention. A subgroup of participants will provide blood samples before and after the intervention to explore possible biological mechanisms related to stress, inflammation, and screening behavior.\n\nThe results may help improve community-based cancer screening programs and provide evidence for using personalized navigation strategies to increase screening participation among high-risk populations.",[468,30,60,61,469,148],"Cancer Screening","Upper Gastrointestinal Cancer","2026-06-24",{"date":188,"type":38},{"date":120,"type":23},{"date":474,"type":23},"2027-02",{"name":476,"class":45},"Hunan Cancer Hospital",{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":24,"phases":487,"briefSummary":488,"conditions":489,"keywords":495,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":506},"100520749","phase-1-safety-and-efficacy-of-obx-115-in-advanced-solid-tumors-100520749","NCT06060613","Safety and Efficacy of OBX-115 in Advanced Solid Tumors","A Phase 1\u002F2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors","Agni-01","Inclusion Criteria:\n\n1. Participant must be 18 years of age or older at the time of signing the informed consent.\n2. Participant has a histologically confirmed diagnosis of advanced\u002Fmetastatic melanoma or relapsed refractory metastatic non-small cell lung cancer (NSCLC).\n3. Cohort and indication specific criteria as follows:\n\n   1. Phase 1 and Phase 2 Cohort 1 (enrollment complete):\n\n      * Participants with unresectable or metastatic melanoma must have experienced documented radiographic disease progression after systemic therapy containing a programmed cell death protein 1 (PD-1)\u002Fprogrammed death ligand 1 (PD-L1) blocking antibody.\n      * Participants with melanoma must not exceed 2 prior lines of systemic therapy. Neoadjuvant\u002FAdjuvant treatment will not be considered a prior line of systemic therapy unless the participant progressed during or within the 12 weeks after the last dose of the adjuvant PD-1\u002FPD-L1 blocking antibody.\n   2. Phase 1 and Phase 2 Cohort 2 (recruiting):\n\n      * Participants with non-small cell lung cancer should have relapsed or are refractory to approved systemic therapies (approved ICI-based regimen for all appropriate participants and\u002For an approved targeted therapy for known molecular abnormalities if applicable to their disease).\n      * Participant must not have been exposed to any second line cytotoxic chemotherapy if they have already received cytotoxic chemotherapy in the first line setting.\n   3. Phase 2 Cohort 3 (recruiting):\n\n      * Participants with unresectable or metastatic melanoma must have experienced documented radiographic disease progression after systemic therapy containing a programmed cell death protein 1 (PD-1)\u002Fprogrammed death ligand 1 (PD-L1) blocking antibody.\n      * Participants with melanoma must not exceed 2 prior lines of systemic therapy. Neoadjuvant\u002FAdjuvant treatment will not be considered a prior line of systemic therapy unless the participant progressed during or within the 12 weeks after the last dose of the adjuvant PD-1\u002FPD-L1 blocking antibody.\n      * Participants with targetable BRAF mutations are not required to have received prior BRAF inhibitors. Participants must not have disease progression on a BRAF\u002FMEK inhibitor that was given as the most recent line of therapy.\n   4. Phase 2 Cohort 4 (recruiting):\n\n      * Participants with frontline unresectable or metastatic melanoma.\n      * Participants may have received up to 2 doses of system therapy containing a programmed cell death protein 1 (PD-1)\u002Fprogrammed death ligand 1 (PD-L1) blocking antibody-based treatment of unresectable metastatic melanoma (but must not have known clinical progression.) Neoadjuvant\u002FAdjuvant treatment will not be considered a prior line of systemic therapy; however, participants whose disease progressed within 12 weeks after the last dose of the PD-1\u002FPD-L1 blocking antibody given as adjuvant treatment (primary ICI resistant) are not eligible.\n4. Participant is assessed as having at least one lesion (or aggregate lesions) suitable for OBX-115 generation.\n5. After tumor tissue procurement, the participant will have at least one remaining measurable lesion, as defined by RECIST v1.1.\n6. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of greater than 6 months.\n7. Participant has recovered from all prior anticancer treatment-related AEs to at least Grade 1 (per Common Terminology Criteria for Adverse Events \\[CTCAE\\]).\n8. Participants must have completed post-operative recovery from any prior surgical procedures with wound healing and resolution of all surgical complications prior to planned tumor procurement surgery.\n9. Both male and female (women of childbearing potential) participants agree to the follow protocol specified contraceptive and\u002For abstinence requirements.\n10. Participant has protocol specified hematologic parameters for absolute neutrophil count (ANC) and platelet count.\n11. Participant has adequate cardiac, liver, lung, and kidney organ function as specified in the protocol.\n\nExclusion Criteria:\n\n1. Participant has melanoma of uveal origin or its other genetic equivalents (e.g. GNA11 and GNAQ).\n2. Participant has a history of brain metastases or leptomeningeal disease. Participants may be considered for enrollment if they have 4 or fewer brain metastatic lesions that are that have been treated, if clinically indicated. Asymptomatic brain metastases that are equivocal or too small to warrant treatment may not be counted towards the above set limits upon discussion and agreement from the Medical Monitor.\n3. Participant has an active medical illness(es) that, in the opinion of the Investigator, would pose increased risks for study participation.\n4. Participants with non-small cell lung cancer with refractory and clinically significant pleural effusions.\n5. Participant has any form of primary or acquired immunodeficiency.\n6. Participant has a history of hypersensitivity to any component of the study intervention.\n7. Participant had another primary malignancy within the previous 3 years (with protocol specified exceptions).\n8. Participant has a history of allogeneic organ transplant, allogeneic cell therapy, or genetically engineered cell therapy. Prior engineered TIL cell therapy is allowed.\n9. Participant requires systemic steroid therapy of greater than10 mg\u002Fday of prednisone or equivalent.\n10. Participant received a live or attenuated vaccination within 28 days prior to the start of lymphodepletion (LD).\n11. Participant has evidence of positive infectious disease screening and\u002For any active uncontrolled viral, bacterial, or fungal disease requiring ongoing systemic treatment or identified during screening.",{"count":486,"type":23},208,[205,174],"This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.",[490,491,430,30,492,493,494],"Tumor Skin","Metastatic Melanoma","Metastatic Lung Cancer","Non Small Cell Lung Cancer","Metastatic Non Small Cell Lung Cancer",[496,497,498,430,30],"Adoptive cell therapy","Tumor Infiltrating Lymphocytes","TIL",{"date":240,"type":38},{"date":501,"type":38},"2023-10-25",{"date":503,"type":23},"2029-06-30",{"name":505,"class":220},"Obsidian Therapeutics, Inc.",10,{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":18,"minAge":514,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":24,"phases":517,"briefSummary":518,"conditions":519,"keywords":542,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":576},"100407463","phase-1-the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle-100407463","NCT04585750","The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","A Phase 1\u002F2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","Inclusion Criteria:\n\n* At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval.\n* Locally advanced or metastatic solid malignancy with a TP53 Y220C mutation\n* Eastern Cooperative Oncology Group (ECOG) status of 0 or 1\n* Previously treated with one or more lines of anticancer therapy and progressive disease\n* Adequate organ function\n* Measurable disease per RECIST v1.1 (Phase 2)\n\nAdditional Criteria for Inclusion in Phase 1b (rezatapopt) + pembrolizumab combination)\n\n* Anti-PD-1\u002FPD-L1 naive or must have progressed on treatment\n* Measurable disease\n\nExclusion Criteria:\n\n* Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug\n* Radiotherapy within 14 days of receiving the study drug\n* Primary CNS tumor\n* History of leptomeningeal disease or spinal cord compression\n* Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptoms\n* Stroke or transient ischemic attack within 6 months prior to screening\n* Heart conditions such as unstable angina within 6 months prior to screening, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities\n* Strong CYP3A4 inducers and strong CYP2C9 inhibitors\u002Finducers within 14 days of first dose of rezatapopt\n* History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication\n* History of prior organ transplant\n* Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer\n* Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection\n\nAdditional Criteria for Exclusion from Phase 2 (rezatapopt monotherapy)\n\n* Known KRAS mutation, defined as a single nucleotide variant (SNV) (Phase 2)\n\nAdditional Criteria for Exclusion from Phase 1b (rezatapopt) + pembrolizumab combination)\n\n* Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE)\n* Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention\n* Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug\n* Hypersensitivity (≥ Grade 3) to pembrolizumab and\u002For any of its excipients\n* Active autoimmune disease that has required systemic treatment in past 2 years\n* History of radiation pneumonitis\n* History of (non-infectious) or active pneumonitis \u002F interstitial lung disease that required steroids\n* Active infection requiring systemic therapy\n* Known history of HIV infection\n* Has previously received rezatapopt","12 Years",{"count":516,"type":23},300,[205,174],"The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.",[520,521,522,523,30,150,143,62,61,60,524,525,149,145,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541],"Advanced Solid Tumor","Advanced Malignant Neoplasm","Metastatic Cancer","Metastatic Solid Tumor","Other Cancer","Locally Advanced","Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )","Small Cell Lung Carcinoma","NSCLC","NSCLC (Non-small Cell Lung Cancer)","SCLC","Non-Small Cell Lung Carcinoma","Triple Negative Breast Cancer","TNBC","HER2+ Breast Cancer","Non-Small Cell Lung Cancer","ER\u002FPR Positive Breast Cancer","HER2- Breast Cancer","HER2-positive Breast Cancer","HER2-negative Breast Cancer","ER\u002FPR(+), Her2(-) Breast Cancer",[543,544,545,546,547,548,549,550,551,552,553,554,182,555,556,557,186,558,559,560,561,562,563,564,565,566,567,568],"PC14586","p53","Y220C","Phase 1","Phase 1\u002F2","PMV","PMV Pharma","p53 mutation","TP53","TP53 mutation","p53 mutant","p53 reactivator","Keytruda","combination","PD-1","anti-PD-1","Merck","MSD","IgG4","mAb","Phase 1b","NGS","Next Generation Sequencing","precision","Phase 2","Rezatapopt",{"date":341,"type":38},{"date":571,"type":38},"2020-10-29",{"date":573,"type":23},"2027-12-31",{"name":575,"class":220},"PMV Pharmaceuticals, Inc",77,{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":587,"conditions":588,"keywords":589,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":46},"100569072","bronchoscopic-microwave-ablation-of-lung-tissue-in-surgical-candidates-100569072","NCT06689488","Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates","Assessment of the Safety and Performance of the AB1 Electrosurgical System for Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates","AB1MALTISC","Inclusion Criteria:\n\nPatients who:\n\n1. Have signed informed consent.\n2. Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.\n3. Are ≥ 18 years old.\n4. Have lung lesion(s)\u002Fnodule(s) which are histopathological-confirmed as cancer.\n5. Have soft tissue lung lesion(s):\n\n   * ≤ 30 mm in the largest dimension of the pulmonary window for Stage A.\n   * ≤ 20 mm in the largest dimension of the pulmonary window for Stage B.\n6. Are candidates for surgical resection as determined by a multi-disciplinary team (MDT) or tumour board.\n7. Greater than 10 mm of tumour-free lung parenchyma between target tumour and pleura or fissure.\n8. Subject is willing and able to comply with the study protocol requirements.\n9. Are assigned an ASA (American Society of Anaesthesiologists) score of ≤ 3 or the patient is deemed fit for general anaesthesia.\n\nExclusion Criteria:\n\nPatients who:\n\n1. Have target nodule(s) within the International Association for the Study of Lung Cancer (IASLC) \"Central Zone\" (including bronchial tree, major vessels, heart, oesophagus, spinal cord, and phrenic \\& laryngeal nerves).\n2. Are pregnant or breast feeding, as determined by standard site practices.\n3. Have participated in an investigational drug or device research study within 30 days of enrolment that would interfere with this study.\n4. Have a physical or psychological condition that would impair study participation or jeopardise the safety or welfare of the subject.\n5. Have an expected survival less than 12 months.\n6. Have bleeding diathesis, uncorrectable coagulopathy, or platelet count ≤ 100 x 10\\^9\u002FL.\n7. Have an implantable device, including pacemakers or other electronic implants.\n8. Have known pulmonary hypertension (PASP \\[pulmonary artery systolic pressure\\] \\>50mmHg).\n9. Who are currently prescribed anticoagulants, clopidogrel or other platelet aggregation inhibitors which can´t be stopped or temporarily withheld.\n10. Subject had a prior pneumonectomy.\n11. Diagnosis of Small Cell Lung Cancer.\n12. Any patient with clinically significant interstitial lung disease in the zone of planned ablation.\n13. Subject had a therapeutic intervention (e.g., SBRT) within same lobe as the target lesion.\n14. Subjects currently undergoing or underwent chemotherapy, systemic immunosuppressive treatment, or radiotherapy within 3 months of planned Study procedure.",{"count":586,"type":23},30,"The overall purpose of this study is to characterise the clinical safety and performance of the Creo Medical MicroBlate™ Flex AB1 instrument in patients with pathologically confirmed malignancy eligible for surgical resection of their nodule, receiving bronchoscopic ablation prior to surgery.",[30],[237,590,591,592],"Ablation","Microwave","Lung cancer","2026-06-23",{"date":341,"type":38},{"date":596,"type":38},"2025-06-17",{"date":598,"type":23},"2026-12",{"name":600,"class":220},"Creo Medical Limited",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":18,"minAge":357,"maxAge":358,"enrollmentInfo":608,"targetDuration":4,"studyType":24,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":125},"100557478","prediction-augmented-screening-initiative-100557478","NCT06538636","Prediction Augmented Screening Initiative","PASI","Inclusion Criteria:\n\nVeterans assigned a PCP at a participating site and who meet inclusion criteria at any point during the study timeframe will be enrolled into the trial. There will be two paths to patient inclusion:\n\n* meeting USPSTF eligibility criteria for LCS, as currently encoded in the background logic of LCS clinical reminders maintained by the VA National Center for Lung Cancer Screening (i.e., age 50-80 years; smoked 20 pack-years; current smoking or quit \\\u003C15 years ago) OR\n* predicted benefit calculated using LYFS-CTVA model exceeds a stringent high-benefit threshold of life-year gains with annual LCS, as recommended in the 2021 CHEST LCS guidelines\n\nExclusion Criteria:\n\n* Veterans who have previously undergone lung cancer screening, are diagnosed with lung cancer, or who do not meet eligibility criteria outlined above",{"count":609,"type":23},23520,[26],"Lung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans. This is because lung cancer is usually diagnosed when the disease has spread, and cure is less likely. Lung cancer screening (LCS) finds cancer at an earlier stage when it is curable, yet only 20% of eligible Veterans have been screened. Uptake is even lower among Black Veterans despite higher lung cancer risk. Using prediction models to identify high-benefit people for whom LCS should be encouraged improves efficiency and reduces disparities. Moreover, it is more patient-centered as shared decision-making conversations can be tailored with personalized information. The US Preventive Services Task Force has called for research to demonstrate that prediction-augmented LCS can be feasibly implemented at the point-of-care. The investigators propose for VA to lead this effort with a large-scale pragmatic clinical trial to show that prediction-augmented LCS is both feasible and improves LCS uptake.",[30,613],"Lung Cancer Screening",{"date":341,"type":38},{"date":616,"type":38},"2026-06-01",{"date":618,"type":23},"2029-09-30",{"name":620,"class":621},"VA Office of Research and Development","FED",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":18,"minAge":357,"maxAge":358,"enrollmentInfo":629,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":631,"conditions":632,"keywords":4,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":636,"leadSponsor":638,"locationsCount":46},"100614465","lung-cancer-screening-implementation-project-in-the-brazilian-public-health-care-system-lusip-100614465","NCT07279948","Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP)","LUSIP","Inclusion Criteria:\n\nIn order, to be eligible for the study, patients must fulfill all the following inclusion criteria:\n\n* Age between ≥50 and ≤80 years.\n* Be a current smoker or have quit 15 years ago or less.\n* Have participated or are currently participating in smoking cessation program.\n* Lifetime smoking exposure equal to or greater than 20 pack-year.\n* Provided signed informed consent (ICF)\n\nExclusion Criteria:\n\n* In order, to be exclude for the study, patients must at least one of the following exclusion criteria:\n\n  * Contraindications to the screening examination: (claustrophobic or weighing more than 130 kgs).\n  * Inability to climb 3 stair steps non-stop (36 steps).\n  * Disabling dyspnea\n  * Symptomatic (with signs and symptoms suspicious of breast cancer lung, namely):\n\n    * pleuritic chest pain\n    * rapidly progressive dyspnea of recent onset\n    * hemoptysis\n    * unexplained hoarseness, lasting more than 1 month.\n    * bone pain\n    * supraclavicular lymphadenopathy or cervical lymphadenopathy persistent\n    * unexplained weight loss of 5% or more of weight in less than 6 months\n    * Previous history of malignant neoplasm (excluding non-melanoma skin cancer) diagnosed less than 10 years before the date of the interview;\n    * Patients with diagnostic of severe psychiatric disease\n    * Immunosuppressed by illness or drugs.\n    * Subjected to anterior lung resection even when determined due to an etiology other than malignant neoplasia.\n    * Person with a serious terminal illness that contraindicates curative lung surgery.",{"count":630,"type":23},477,"A prospective, longitudinal, single-arm interventional study of lung cancer screening.",[30],"2026-06-22",{"date":447,"type":38},{"date":188,"type":23},{"date":637,"type":23},"2027-01-31",{"name":372,"class":220},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":4,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":24,"phases":648,"briefSummary":649,"conditions":650,"keywords":654,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":662,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":98},"100414594","phase-1-a-trial-of-rsc-1255-for-treatment-of-patients-with-advanced-malignancies-100414594","NCT04678648","A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies","A Phase Ia\u002FIb, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies","Inclusion Criteria (Key Factors):\n\n1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:\n\n   * Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition\n   * Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit\n   * Malignancy has progressed on standard therapy\n2. Has evaluable or measurable tumor(s) in dose-escalation by standard radiological and\u002For laboratory assessments as applicable to their malignancy.\n3. Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG).\n4. Is age ≥ 18 years.\n5. Has either tissue agnostic tumors and documented RAS mutations or with glioblastoma with or without mutation in RAS\n\nExclusion Criteria (Key Factors):\n\n1. Participants receiving cancer therapy at the time of enrollment.\n2. Any clinically significant disease or condition affecting a major organ system.\n3. Significant cardiovascular disease or electrocardiogram (ECG) abnormalities.\n4. Known Gilbert's disease.\n5. Has had a previous (within 2 years) or has a current malignancy other than the target cancer.\n6. Intermittent hypokalemia\n7. Grade 1 or higher nausea, vomiting, diarrhea at baseline due to underlying disease",{"count":647,"type":23},134,[205],"RSC-101 is a Phase 1a\u002F1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.",[651,652,30,142,653,151],"Advanced Malignant Solid Neoplasm","RAS Mutation","Glioblastoma",[655,314,656,657,364,658,653,659,660,661],"Malignancy","Refractory","RAS mutation","Colon","RSC-1255","Progression","Pancreatic",{"date":593,"type":38},{"date":664,"type":38},"2021-03-03",{"date":666,"type":23},"2027-01-30",{"name":668,"class":220},"RasCal Therapeutics, Inc.",{"id":670,"slug":671,"hasResults":12,"nctId":672,"briefTitle":673,"officialTitle":674,"acronym":4,"eligibilityCriteria":675,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":676,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":678,"conditions":679,"keywords":680,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":681,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":46},"100125345","studying-tumor-tissue-samples-and-blood-samples-to-learn-more-about-dna-changes-in-patients-with-lung-cancer-100125345","NCT00899405","Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer","EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood","DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed lung cancer\n\nPATIENT CHARACTERISTICS:\n\n* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n* May have received prior EGFR inhibitors",{"count":677,"type":23},800,"RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.\n\nPURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.",[30],[338],{"date":447,"type":38},{"date":683,"type":38},"2004-05-19",{"date":685,"type":23},"2034-05",{"name":687,"class":45},"University of California, Davis",{"id":689,"slug":690,"hasResults":12,"nctId":691,"briefTitle":692,"officialTitle":693,"acronym":4,"eligibilityCriteria":694,"healthyVolunteers":12,"sex":18,"minAge":83,"maxAge":358,"enrollmentInfo":695,"targetDuration":4,"studyType":24,"phases":697,"briefSummary":698,"conditions":699,"keywords":700,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":706,"lastUpdatePostDateStruct":707,"startDateStruct":708,"completionDateStruct":709,"leadSponsor":711,"locationsCount":46},"100313158","phase-1-antigen-specific-t-cells-against-lung-cancer-100313158","NCT03356808","Antigen-specific T Cells Against Lung Cancer","Multicenter Trial of Cancer Antigen-specific T Cells in the Treatment of Lung Cancer","Inclusion Criteria:\n\n1. Patients with stage III, IV or relapsed lung cancer confirmed by histology and biopsy.\n2. Age: ≥ 18 years and ≤ 80 years.\n3. 4 weeks at least since last chemotherapy or radiotherapy and 2 weeks at least since last systemic steroid hormone and other immunosuppressive therapy.\n4. Side Effects of Chemotherapy have subsided.\n5. Cancer specific antigens are identified and shown to express at high levels (\\>2+) in malignant tissues by immuno-histochemical staining or flow cytometry.\n6. Karnofsky\u002FLansky ≥ 50%.\n7. Expected survival ≥ 6 weeks.\n\nInitial hematopoietic conditions with\n\n* neutrophils (ANC) ≥ 1×10\\^6\u002FL;\n* platelet (PLT) ≥ 1×10\\^8\u002FL.\n\nProper renal and hepatic functions (ULN denotes \"upper limit of normal range\") with\n\n* serum creatinine ≤ 2×ULN;\n* serum bilirubin ≤ 3×ULN;\n* AST\u002FALT ≤ 5×ULN.\n\n  10\\. Oxygen saturation ≥ 90%. 11. Written, informed consent obtained prior to any study-specific procedures.\n\nExclusion Criteria:\n\n1. Airway obstruction caused by tumor.\n2. History of epilepsy or other central nervous system diseases.\n3. Patients who require systemic corticosteroid or other immunosuppressive therapy.\n4. History of prolonged or serious heart disease during QT.\n5. history of serious cyclophosphamide toxicity.\n6. Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in any immune cell therapy study.\n\nInadequate liver and renal function with\n\n* serum creatinine \\> 2.5 mg\u002Fdl;\n* serum (total) bilirubin \\> 2.0 mg\u002Fdl;\n* AST \\& ALT \\> 3 x ULN.\n\n  8\\. Pregnant or lactating females. 9. Serious active infection during screening. 10. Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection.\n\n  11\\. Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.",{"count":696,"type":23},20,[205,174],"The purpose of this clinical trial is to assess the feasibility, safety and efficacy of cancer antigen-specific T cells targeting lung cancer. The cancer targeting antigens are identified through immunostaining of patient's cancer specimens. Another goal of the study is to learn more about the persistence and function of the ex vivo manipulated antigen-specific T cells in the body.",[30],[592,701,702,703,704,705],"CAR-T","mesothelin","Muc1","GD2","MAGE-A4","2026-06-18",{"date":593,"type":38},{"date":616,"type":38},{"date":710,"type":23},"2030-12-31",{"name":712,"class":45},"Shenzhen Geno-Immune Medical Institute",{"id":714,"slug":715,"hasResults":12,"nctId":716,"briefTitle":717,"officialTitle":718,"acronym":4,"eligibilityCriteria":719,"healthyVolunteers":12,"sex":18,"minAge":276,"maxAge":463,"enrollmentInfo":720,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":722,"conditions":723,"keywords":724,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":726,"lastUpdatePostDateStruct":727,"startDateStruct":728,"completionDateStruct":730,"leadSponsor":731,"locationsCount":46},"100544992","lung-cancer-screening-program-using-low-dose-tomography-and-metabolomic-evaluation-in-a-public-service-100544992","NCT06376097","Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.","Implementation of a Lung Cancer Screening Program in a Public Service, Using Low-dose Tomography and Metabolomics Evaluation","Inclusion Criteria:\n\nAge between 45 and 74 years old; Smoker with a smoking history of at least 30 pack-years or former smoker who has quit smoking for less than 15 years; Never having participated in a lung cancer screening program ; Signing of the free and informed consent form.\n\nExclusion Criteria:\n\nPatients with chronic diseases (cardiovascular, pulmonary, hepatic, renal or metabolic) at an advanced stage that limit life expectancy or make it impossible to perform a curative surgical procedure; Patients being treated for tuberculosis or other granulomatous diseases; Patients diagnosed with previous neoplasm(s) that could develop lung metastases; Pregnant women; Patients who, for some reason, are unable to undergo low-dose chest computed tomography; Patients previously submitted to thoracic radiotherapy.",{"count":721,"type":23},1000,"Observational study that aims to evaluate the implementation of a lung cancer screening program in a smoker population included in a public heath service.",[30],[725],"Observational; Lung Cancer; Screening;","2026-06-17",{"date":706,"type":38},{"date":729,"type":38},"2023-04-19",{"date":240,"type":23},{"name":372,"class":220}]